|
1
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang H, Shen F, Han J, Shen YN, Xie GQ,
Wu MC and Yang T: Epidemiology and surgical management of
intrahepatic cholangiocarcinoma. Hepat Oncol. 3:83–91. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bergquist A and von Seth E: Epidemiology
of cholangiocarcinoma. Best Pract Res Clin Gastroenterol.
29:221–232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu J and Yin B: Advances in biomarkers of
biliary tract cancers. Biomed Pharmacother. 81:128–135. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Esnaola NF, Meyer JE, Karachristos A,
Maranki JL, Camp ER and Denlinger CS: Evaluation and management of
intrahepatic and extrahepatic cholangiocarcinoma. Cancer.
122:1349–1369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Squadroni M, Tondulli L, Gatta G, Mosconi
S, Beretta G and Labianca R: Cholangiocarcinoma. Crit Rev Oncol
Hematol. 116:11–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu AX: Future directions in the treatment
of cholangiocarcinoma. Best Pract Res Clin Gastroenterol.
29:355–361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rizvi S and Gores GJ: Emerging molecular
therapeutic targets for cholangiocarcinoma. J Hepatol. 67:632–644.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mertens JC, Rizvi S and Gores GJ:
Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis.
1864:1454–1460. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghouri YA, Mian I and Blechacz B: Cancer
review: Cholangiocarcinoma. J Carcinog. 14:12015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jusakul A, Cutcutache I, Yong CH, Lim JQ,
Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM,
Choo SP, et al: Whole-genome and epigenomic landscapes of
etiologically distinct subtypes of cholangiocarcinoma. Cancer
Discov. 7:1116–1135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
13
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43((Database Issue)): D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng Y, Long J, Wu L, Zhang H, Li L,
Zheng Y, Wang A, Lin J, Yang X, Sang X, et al: Identification of
hub genes involved in the development of hepatocellular carcinoma
by transcriptome sequencing. Oncotarget. 8:60358–60367.
2017.PubMed/NCBI
|
|
15
|
Wang X, Hu KB, Zhang YQ, Yang CJ and Yao
HH: Comprehensive analysis of aberrantly expressed profiles of
lncRNAs, miRNAs and mRNAs with associated ceRNA network in
cholangiocarcinoma. Cancer Biomarkers. 23:549–559. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Anders S and Huber W: Differential
expression analysis for sequence count data. Genome Biol.
11:R1062010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Team RDC: R: A language and environment
for statistical computing. Journal. 2010.
|
|
18
|
Walter W, Sánchez-Cabo F and Ricote M:
GOplot: An R package for visually combining expression data with
functional analysis. Bioinformatics. 31:2912–2914. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choi JK, Yu U, Yoo OJ and Kim S:
Differential coexpression analysis using microarray data and its
application to human cancer. Bioinformatics. 21:4348–4355. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chaisaingmongkol J, Budhu A, Dang H,
Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y,
Bhudhisawasdi V, Lertprasertsuke N, et al: Common molecular
subtypes among asian hepatocellular carcinoma and
cholangiocarcinoma. Cancer Cell. 32:57–70.e53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Andersen JB, Spee B, Blechacz BR, Avital
I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts
LR, et al: Genomic and genetic characterization of
cholangiocarcinoma identifies therapeutic targets for tyrosine
kinase inhibitors. Gastroenterology. 142:1021–1031.e15. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oishi N, Kumar MR, Roessler S, Ji J,
Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, et al:
Transcriptomic profiling reveals hepatic stem-like gene signatures
and interplay of miR-200c and epithelial-mesenchymal transition in
intrahepatic cholangiocarcinoma. Hepatology. 56:1792–1803. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sulpice L, Rayar M, Desille M, Turlin B,
Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K,
Clément B and Coulouarn C: Molecular profiling of stroma identifies
osteopontin as an independent predictor of poor prognosis in
intrahepatic cholangiocarcinoma. Hepatology. 58:1992–2000. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sulpice L, Desille M, Turlin B, Fautrel A,
Boudjema K, Clément B and Coulouarn C: Gene expression profiling of
the tumor microenvironment in human intrahepatic
cholangiocarcinoma. Genom Data. 7:229–232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Therneau TM: A package for survival
analysis in S. version 2.38. 2015, https://CRAN.R-project.org/package=survival
|
|
28
|
Terry M and Therneau PMG: Modeling
Survival data: Extending the Cox ModelDietz K, Gail M, Krickeberg
K, Samet J and Tsiatis A: Springer; New York, NY: 2000
|
|
29
|
Holt LJ, Tuch BB, Villen J, Johnson AD,
Gygi SP and Morgan DO: Global analysis of Cdk1 substrate
phosphorylation sites provides insights into evolution. Science.
325:1682–1686. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ravindran Menon D, Luo Y, Arcaroli JJ, Liu
S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC,
et al: CDK1 Interacts with Sox2 and promotes tumor initiation in
human melanoma. Cancer Res. 78:6561–6574. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okumura E, Fukuhara T, Yoshida H, Hanada
Si S, Kozutsumi R, Mori M, Tachibana K and Kishimoto T: Akt
inhibits Myt1 in the signalling pathway that leads to meiotic
G2/M-phase transition. Nat Cell Biol. 4:111–116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wattanawongdon W, Hahnvajanawong C, Namwat
N, Kanchanawat S, Boonmars T, Jearanaikoon P, Leelayuwat C,
Techasen A and Seubwai W: Establishment and characterization of
gemcitabine-resistant human cholangiocarcinoma cell lines with
multidrug resistance and enhanced invasiveness. Int J Oncol.
47:398–410. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Booth DG, Takagi M, Sanchez-Pulido L,
Petfalski E, Vargiu G, Samejima K, Imamoto N, Ponting CP, Tollervey
D, Earnshaw WC and Vagnarelli P: Ki-67 is a PP1-interacting protein
that organises the mitotic chromosome periphery. Elife.
3:e016412014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Klöppel G and La Rosa S: Ki67 labeling
index: Assessment and prognostic role in gastroenteropancreatic
neuroendocrine neoplasms. Virchows Arch. 472:341–349. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miller HC, Drymousis P, Flora R, Goldin R,
Spalding D and Frilling A: Role of Ki-67 proliferation index in the
assessment of patients with neuroendocrine neoplasias regarding the
stage of disease. World J Surg. 38:1353–1361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Singh S, Hallet J, Rowsell C and Law CHL:
Variability of Ki67 labeling index in multiple neuroendocrine
tumors specimens over the course of the disease. Eur J Surg Oncol.
40:1517–1522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Grillo F, Albertelli M, Brisigotti MP,
Borra T, Boschetti M, Fiocca R, Ferone D and Mastracci L: Grade
increases in gastroenteropancreatic neuroendocrine tumor metastases
compared to the primary tumor. Neuroendocrinology. 103:452–459.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Romero A, Martín M, Cheang MC, López
García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ,
Arroyo Fernández M, Díaz Rubio E, et al: Assessment of
Topoisomerase II α status in breast cancer by quantitative PCR,
gene expression microarrays, immunohistochemistry, and fluorescence
in situ hybridization. Am J Pathol. 178:1453–1460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Järvinen TA and Liu LE: Simultaneous
amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A)
genes-molecular basis for combination chemotherapy in cancer. Curr
Cancer Drug Targets. 6:579–602. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi
X, Zhang J and Liu T: Analysis of EGFR, HER2, and TOP2A gene status
and chromosomal polysomy in gastric adenocarcinoma from Chinese
patients. BMC Cancer. 8:3632008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Press MF, Sauter G, Buyse M, Bernstein L,
Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T,
Martin M, et al: Alteration of topoisomerase II-alpha gene in human
breast cancer: Association with responsiveness to
anthracycline-based chemotherapy. J Clin Oncol. 29:859–867. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Simon R, Atefy R, Wagner U, Forster T,
Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T and Sauter G:
HER-2 and TOP2A coamplification in urinary bladder cancer. Int J
Cancer. 107:764–772. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Panvichian R, Tantiwetrueangdet A,
Angkathunyakul N and Leelaudomlipi S: TOP2A amplification and
overexpression in hepatocellular carcinoma tissues. Biomed Res Int.
2015:3816022015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nateewattana J, Dutta S, Reabroi S, Saeeng
R, Kasemsook S, Chairoungdua A, Weerachayaphorn J, Wongkham S and
Piyachaturawat P: Induction of apoptosis in cholangiocarcinoma by
an andrographolide analogue is mediated through topoisomerase II
alpha inhibition. Eur J Pharmacol. 723:148–155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gil J and O'Loghlen A: PRC1 complex
diversity: Where is it taking us? Trends Cell Biol. 24:632–641.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang H, Xiao G, Behrens C, Schiller J,
Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, et al: A
12-gene set predicts survival benefits from adjuvant chemotherapy
in non-small cell lung cancer patients. Clin Cancer Res.
19:1577–1586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sasaki M, Yamaguchi J, Ikeda H, Itatsu K
and Nakanuma Y: Polycomb group protein Bmi1 is overexpressed and
essential in anchorage-independent colony formation, cell
proliferation and repression of cellular senescence in
cholangiocarcinoma: Tissue and culture studies. Hum Pathol.
40:1723–1730. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sasaki M, Yamaguchi J, Itatsu K, Ikeda H
and Nakanuma Y: Over-expression of polycomb group protein EZH2
relates to decreased expression of p16 INK4a in
cholangiocarcinogenesis in hepatolithiasis. J Pathol. 215:175–183.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hu CK, Coughlin M and Mitchison TJ:
Midbody assembly and its regulation during cytokinesis. Mol Biol
Cell. 23:1024–1034. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sadler JBA, Wenzel DM, Williams LK,
Guindo-Martínez M, Alam SL, Mercader JM, Torrents D, Ullman KS,
Sundquist WI and Martin-Serrano J: A cancer-associated polymorphism
in ESCRT-III disrupts the abscission checkpoint and promotes genome
instability. Proc Natl Acad Sci USA. 115:E8900–E8908. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fu Y, Huang J, Wang KS, Zhang X and Han
ZG: RNA interference targeting CITRON can significantly inhibit the
proliferation of hepatocellular carcinoma cells. Mol Biol Rep.
38:693–702. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Estey MP, Di Ciano-Oliveira C, Froese CD,
Fung KY, Steels JD, Litchfield DW and Trimble WS: Mitotic
regulation of SEPT9 protein by cyclin-dependent kinase 1 (Cdk1) and
Pin1 protein is important for the completion of cytokinesis. J Biol
Chem. 288:30075–30086. 2013. View Article : Google Scholar : PubMed/NCBI
|
